On May 22, 2023, Solid Biosciences Inc. and Carl Morris entered into an executive transition and separation agreement (the “Separation Agreement”) providing for Dr. Morris' resignation as Chief Scientific Officer, Neuromuscular of the Company. The effective date of Dr. Morris' resignation is July 14, 2023 (the “Separation Date”). On the Separation Date, the Company and Dr. Morris intend to enter into a consulting agreement (the “Consulting Agreement”), pursuant to which Dr. Morris will assist with the transition of his duties and provide other consulting and advisory services, as requested from time to time by the Company.

Following the Separation Date, Jennifer Marlowe, Chief Scientific Officer, Friedreich's Ataxia and Cardiac Pipeline of the Company, will assume Dr. Morris' responsibilities and serve as Chief Scientific Officer of the Company.